Basic study on new treatment strategy targeting mevalonate pathway in prostate cancer

在这项研究中，他汀类药物和唑来多隆酸，甲氧戊酸通路靶向剂，被研究的治疗潜力。这两种药物都能抑制前列腺癌细胞的增殖，尤其是他汀类药物能特异性地抑制雄激素非依赖性PC-3细胞的增殖。前列腺癌细胞表达低密度脂蛋白受体。LNCaP细胞具有调节低密度脂蛋白受体表达的能力，以响应外源性或内源性脂质水平。相反，PC-3缺乏这种能力，他汀类药物在PC-3细胞中发挥其抗增殖作用。这些结果表明甲伐他汀类靶向药物，如他汀类和唑来度酸，有可能用于前列腺癌的治疗。

In this study, the therapeutic potential of statin and zoledoronic acid, mevalotate pathway targeting agents, was studied. Both agents inhibited prostate cancer cell proliferations, especially, statins specifically inhibited proliferation of PC-3, androgen-independent cells. Prostate cancer cells expressed LDL receptor. LNCAP cells had abilities to regulate expression of LDL receptor in response to exogeneous or endogenouse lipid levels. In contrast, PC-3 lacked this ability and statin exerts its antiproliferative effect in PC-3 cells. These results suggested that mevalonate targeting agents, such as statin and zoledoronic acid, have potentials to use for prostate cancer.